BioCardia Announces Participation at the A.G.P. Biotech & Specialty Pharma Conference October 13, 2021 (Virtual Conference)

Rhea-AI Summary

BioCardia (Nasdaq: BCDA) announced its participation in the A.G.P Biotech & Specialty Pharma Conference scheduled for October 13, 2021. The event will feature one-on-one meetings with management, led by CEO Dr. Peter Altman. This conference aims to connect institutional and retail investors with BioCardia's leadership. The company specializes in developing cellular therapies targeting cardiovascular diseases, with notable products including CardiAMP and NK1R+ platforms.

Positive

• Participation in a prominent biotechnology conference enhances visibility and investor engagement.
• Opportunity for direct interaction between management and investors could attract new interest and investments.

Negative

• None.

SAN CARLOS, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- BioCardia^®, Inc. (Nasdaq: BCDA), a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular diseases, today announced it will be participating in the A.G.P Biotech & Specialty Pharma Conference taking place virtually on October 13, 2021.

Dr. Peter Altman, CEO of BioCardia, will be participating in one-on-one meetings at the conference. If you are an institutional or retail investor, and would like to request a 1:1 meeting with BioCardia management, please contact your A.G.P representative or click on the following link to register for the conference and request a meeting: A.G.P Biotech & Specialty Pharma Conference

Event: A.G.P. Fall Biotech & Specialty Pharma Conference

Date: October 13^th, 2021

Format: 1x1 Meetings

Location: Virtual conference

About BioCardia^®
BioCardia, Inc., headquartered in San Carlos, California, is a developer of two biotherapeutic platforms – the CardiAMP™ autologous bone marrow derived mononuclear cell therapy for cardiovascular indications, and the NK1R+ allogenic bone marrow derived mesenchymal stem cell therapies for cardiovascular and pulmonary diseases. These platforms underly four product candidates, each with the potential to meaningfully benefit millions of patients. Three of these investigational therapies are enabled by the Company’s proprietary biotherapeutic delivery platforms, which the Company also selectively licenses to other biotherapeutic development firms. For more information, visit www.BioCardia.com.

INVESTOR CONTACT:
David McClung, Chief Financial Officer
investors@BioCardia.com
(650) 226-0120

MEDIA CONTACT:
Anne Laluc, Marketing
Email: alaluc@BioCardia.com
Phone: 650-226-0120

FAQ

When is the A.G.P Biotech & Specialty Pharma Conference for BioCardia scheduled?

The conference is scheduled for October 13, 2021.

What is the focus of BioCardia?

BioCardia focuses on developing therapies for cardiovascular diseases through cellular and cell-derived methods.

Who will represent BioCardia at the conference?

Dr. Peter Altman, CEO of BioCardia, will represent the company.

How can investors meet with BioCardia management?

Investors can request one-on-one meetings through their A.G.P representative or by registering for the conference.

What products does BioCardia develop?

BioCardia develops the CardiAMP and NK1R+ biotherapeutic platforms for cardiovascular conditions.